ACS-WRAP: Applying Evidence to Patient Management

Integrating Bivalirudin into Practice Algorithms for ACS and STEMI

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

September 1, 2008

Expiration Date:

September 1, 2010

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: cardiologists, interventional cardiologists, emergency physicians, hospitalists and hospital pharmacists.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from The Medicines Company.
 

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Harold L. Dauerman, MD, FACC
Professor of Medicine
University Cardiology Associates
University of Vermont College of Medicine
Director, Cardiovascular Catheterization Laboratory
Fletcher Allen Health Care
Burlington, Vermont

Faculty Disclosures:

Dr. Dauerman reports that he has received consultant fees from The Medicines Company and Abbott Vascular, and research grants from Abbott Vascular and Boston Scientific. He has also received fellowship support from Boston Scientific, Cordis/JNJ and Medtronic

Educational Objectives:

After viewing this program, physicians, pharmacists, and other healthcare providers will:

• Be able to identify signs, symptoms, and prognostic features of acute coronary syndrome and related ischemic conditions, and their implications for invasive vascular management.
• Be able to describe how recently issued AHA/ACC Guidelines for Non ST-Elevation Myocardial Infarction are best applied to appropriately risk-stratified patients with UA and NSTEMI.
• Be able to assess and implement optimal pharmacologic interventions, especially antithrombotic therapy in the upstream setting, for patients presenting with manifestations of UA, NSTEMI, STEMI, and related conditions.
• Be able to understand the implications of recent clinical data, trials, and recommendations on switching antithrombotic therapy in patients who present with acute ischemic coronary syndromes, with an emphasis on determining when switching from one agent to another is appropriate, safe, and feasible, and when switching among antithrombotic agents may be problematic.
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved